Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
UF startup Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it has... Read More
Axogen, Inc. Announces Full Launch of Avive+ Soft Tissue Matrix™
UF startup Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced the launch of its newest product, Avive+ Soft Tissue Matrix™.
AxoGen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
UF startup and UF Innovate | Accelerate graduate Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the first surgical implantations of its newest product, Avive+ Soft Tissue Matrix™.
Axogen Announces Plan for CEO Leadership Transition
UF startup and UF Innovate | Sid Martin Biotech alum Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that President and Chief Executive Officer (CEO) Karen Zaderej plans to retire from the company by January 2025.
CEO of UF Startup AxoGen is appointed to EyePoint Pharmaceuticals Board of Directors
EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the appointment of Karen Zaderej to its Board of Directors. Ms. Zaderej is currently the President, Chief Executive Officer and Chair of the Board at UF Startup and Accelerate graduate AxoGen, Inc., and brings more than 35 years of biopharmaceutical and medical device experience to the role.
Talking About Feeling: Axogen Raises Awareness for Mastectomy Side Effect
In the wake of Breast Cancer Awareness Month, UF startup and UF Innovate | Accelerate at Sid Martin Biotech graduate Axogen has expanded the scope of a campaign to raise awareness about a side effect of mastectomies.
Axogen RECON(SM) Clinical Study Completes Subject Follow-Up
UF startup and UF Innovate | Sid Martin Biotech graduate Axogen, a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, announced that the RECON Clinical Study supporting its Biologics License Application (BLA) for Avance Nerve Graft has completed follow-up of study subjects.
CFO of Life Science Startup Axogen Shares How Firm Navigated Pandemic’s Health Care Disruptions
UF startup and UF Innovate | Sid Martin Biotech graduate Axogen, a life science company that is developing products for nerve repair, is ramping up hiring for scientists and engineers after navigating through the negative disruptions from the Covid-19 pandemic.
Axogen’s Aim: Growing Tampa Into a Hub for Nerve Repair Treatment Technology
As a biotech company at the forefront of nerve repair treatment, UF startup and UF Innovate | Sid Martin Biotech alum Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, has always been near the front of the scientific curve.
AxoGen’s Avance Nerve Graft Helps Woman Race Horses Again
Woman returns to horse racing after AxoGen's Avance nerve graft relieved her excruciating foot pain caused by osteoarthritis and surgeries.
